Pharmaceuticals

Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Valuation and Growth Prospects: $13.17 Billion by 2029

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the anti-vascular endothelial growth factor therapeutics market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Anti-Vascular Endothelial Growth Factor Therapeutics Market Size?

The anti-vascular endothelial growth factor therapeutics market has experienced a slight decrease in size over recent years. It is projected to transition from $12.2 billion in 2024 to $12.17 billion in 2025, demonstrating a compound annual growth rate (CAGR) of -0.2%. Historically, the expansion of this market was attributable to an increase in age-related macular degeneration, a higher incidence of diabetic retinopathy, progress in retinal disease diagnosis, proven clinical success and efficacy, and a move towards outpatient treatment.

The anti-vascular endothelial growth factor therapeutics market is anticipated to experience slight expansion over the coming years. This market is projected to reach $13.17 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 2.0%. Factors contributing to this growth during the forecast period include a rise in the aging population and ocular diseases, broadening uses in retinal conditions, the creation of advanced therapeutics, greater focus on early treatment, and worldwide health programs improving access to care. Key trends anticipated for the forecast period encompass their increased use in cancer therapy, a move towards combination treatments in ophthalmology, the investigation of biosimilar alternatives, studies into resistance mechanisms, and their incorporation with imaging technologies.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10683&type=smp

What Core Market Drivers Are Expanding The Anti-Vascular Endothelial Growth Factor Therapeutics Industry?

The increasing prevalence of ophthalmic diseases is anticipated to drive the expansion of the anti-vascular endothelial growth factor therapeutics market in the future. The prevalence of ophthalmic diseases refers to the count or proportion of individuals within a given population who have been diagnosed with or exhibit specific eye conditions or ailments. Anti-vascular endothelial growth factor (VEGF) therapeutics contribute to reducing the occurrence of ophthalmic diseases by effectively treating conditions such as wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. For instance, in October 2022, according to the World Health Organization, a Switzerland-based international public health organization, globally, approximately 2.2 billion people have near or distance vision impairment, and 1 billion people suffer from near or distance vision impairment. Furthermore, among these, 88.4 million are suffering from refractive error, 94 million have cataracts, 8 million have age-related macular degeneration, and around 3.9 million have diabetic retinopathy. Therefore, the rise in the prevalence of ophthalmic diseases is fueling the growth of the anti-vascular endothelial growth factor therapeutics market.

What Segment Insights Are Highlighted In The Anti-Vascular Endothelial Growth Factor Therapeutics Market Report?

The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented –

1) By Product: Eylea, Lucentis, Beovu

2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration

3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users

Subsegments:

1) By Eylea: Indications, Dosage Forms

2) By Lucentis: Indications, Dosage Forms

3) By Beovu: Indications, Dosage Forms

Which Notable Trends Are Transforming The Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook?

A prominent trend gaining traction in the anti-vascular endothelial growth factor therapeutics market involves advancements in therapies. To sustain their market standing, companies within the anti-vascular endothelial growth factor therapeutics market are implementing advanced therapeutic solutions. For example, in May 2022, Ashvattha Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, disclosed phase 1 safety data from healthy subjects for its subcutaneous anti-VEGF candidates aimed at wet AMD (age-related macular degeneration) and DME (diabetic macular edema). The D-4517.2 therapy is a novel, first-in-class treatment specifically designed to address unmet needs in DME conditions. This D-4517.2 therapy is being developed for self-administration utilizing an autoinjector, which will allow patients to administer the medication once a month comfortably at home.

Which Firms Are Driving Innovation Within The Anti-Vascular Endothelial Growth Factor Therapeutics Market?

Major companies operating in the anti-vascular endothelial growth factor therapeutics market include F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., Coherus BioSciences Inc., Eli Lilly and Company, Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc, Allergan Inc., Novartis AG, kyowa Kirin Co. Ltd., Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/anti-vascular-endothelial-growth-factor-therapeutics-global-market-report

What Regional Trends Are Shaping Growth In The Anti-Vascular Endothelial Growth Factor Therapeutics Market?

North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2024.Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=10683&type=smp

Browse Through More Reports Similar to the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market 2025, By The Business Research Company

Protein Expression Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/protein-expression-global-market-report

Insecticides Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/insecticides-global-market-report

Pesticide And Other Agricultural Chemicals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pesticide-and-other-agricultural-chemicals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795